You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb) – A team led by researchers at the Broad Institute and Brigham and Women's Hospital has developed a high-throughput platform for identifying small molecules that can disrupt the genome editing activity of CRISPR-Cas nucleases.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
Don't have a GenomeWeb or 360Dx account?Register for Free.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.
A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.
NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.
In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.
The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression.
As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.
In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.